Isis Pharmaceuticals has collaborated with Biogen Idec for a second time for the development and commercialisation of an antisense drug candidate for the rare genetic neuromuscular disease myotonic dystrophy type 1 (DM1)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: PharmaDeals Ltd